Azithromycin does not reduce recurrent coronary events

Lowe, G.D.O. (2004) Azithromycin does not reduce recurrent coronary events. Evidence-Based Healthcare, 8(2), pp. 105-106. (doi: 10.1016/j.ehbc.2004.02.019)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1016/j.ehbc.2004.02.019

Abstract

Question<br />Does azithromycin reduce the incidence of coronary events in people with a previous myocardial infarction?<br />Study design<br />Double-blind randomised placebo-controlled trial.<br />Main results<br />There was no difference in the number of combined primary events in people treated with azithromycin compared to placebo (RR 7%, 95% CI -5% to +17%), or any individual type of event (p≥0.31). This result did not change after adjusting the analysis for cardiac risk factors. Gastrointestinal tract-related adverse events were more common with azithromycin compared with placebo (e.g. diarrhoea 8.1% vs. 1.4%, statistical significance not reported). Respiratory tract adverse events were less common in the azithromycin group (6.4% vs. 9.4%,p<0.001).<br />Authors' conclusions<br /> Treatment with azithromycin in stable patients with a history of myocardial infarction does not reduce the rate of coronary heart disease events.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Lowe, Professor Gordon
Authors: Lowe, G.D.O.
Subjects:R Medicine > RC Internal medicine
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Evidence-Based Healthcare
ISSN:1462-9410

University Staff: Request a correction | Enlighten Editors: Update this record